1
|
Rao PN, Deo DD, Gaur A, Baran DA, Zucker MJ, Kapoor S, Marchioni MA, Almendral J, Kandula P, Patel A. A new flow cytometry assay identifies recipient IgG subtype antibodies binding donor cells: increasing donor availability for highly sensitised patients. Clin Transl Immunology 2022; 11:e1415. [PMID: 36092480 PMCID: PMC9446897 DOI: 10.1002/cti2.1415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2021] [Revised: 07/13/2022] [Accepted: 08/22/2022] [Indexed: 11/25/2022] Open
Abstract
Objectives There are four immunoglobulin (IgG) subtypes that have varying complement‐activating ability: strong (IgG3 and IgG1) and weak (IgG2 and IgG4). The standard flow cytometric crossmatch (FCM) assay does not distinguish between the various subtypes of the IgG molecule. This study outlines the development and use of a novel cell‐based IgG subtype‐specific FCM assay that is able to detect the presence of and quantitate the IgG subtypes bound to donor cells. Methods A six‐colour lyophilised reagent was designed that specifically detects the four IgG subtypes, as well as distinguishes between T cells and B cells in the lymphocyte population. To test the efficacy of this reagent, a retrospective evaluation of a group of highly sensitised patients awaiting heart and kidney transplant was carried out, who, because of positive standard FCM results, had been deemed incompatible with numerous prior potential donors. Results Observations in this study demonstrate that the positive standard FCM results were mainly because of the presence of noncomplement‐activating IgG2 or IgG4 antibodies. The results were supported by the absence of C3d‐binding donor‐specific antibodies (DSA) and a negative complement‐dependent cytotoxicity crossmatch (CDC). Conclusion Preliminary data presented in this study demonstrate the reliability of the novel IgG subtype assay to detect the presence of pretransplant, complement‐activating antibodies bound to donor cells. The knowledge gained from the IgG subtype assay and the C3d‐binding specificities of DSAs provides improved identification of donor suitability in pretransplant patients, potentially increasing the number of transplants.
Collapse
Affiliation(s)
- Prakash N Rao
- Personalized Transplant Medicine Institute New Providence NJ USA
| | - Dayanand D Deo
- Personalized Transplant Medicine Institute New Providence NJ USA
| | | | | | | | | | | | | | | | - Anup Patel
- Robert Wood Johnson Barnabas Health Livingston NJ USA
| |
Collapse
|
2
|
Guglin M, Zucker MJ, Borlaug BA, Breen E, Cleveland J, Johnson MR, Panjrath GS, Patel JK, Starling RC, Bozkurt B. Evaluation for Heart Transplantation and LVAD Implantation. J Am Coll Cardiol 2020; 75:1471-1487. [DOI: 10.1016/j.jacc.2020.01.034] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 01/02/2020] [Accepted: 01/07/2020] [Indexed: 12/11/2022]
|
3
|
Baran DA, Rao P, Deo D, Zucker MJ. Differential gene expression in non-adherent heart transplant survivors: Implications for regulatory T-cell expression. Clin Transplant 2020; 34:e13834. [PMID: 32072690 DOI: 10.1111/ctr.13834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 01/27/2020] [Accepted: 02/16/2020] [Indexed: 11/30/2022]
Abstract
Survival despite prolonged non-adherence with immunosuppression is rare but has been reported in kidney, lung, and liver transplantation. Its occurrence in heart transplantation is quite rare. Our study was prompted by an index patient who survived despite prolonged medication non-adherence. Prospective consent and blood collection were conducted for seven additional patients who presented in a similar fashion. The blood of patients who were diagnosed with rejection, stable early post-transplant, and stable more than 5 years post-transplant were all compared with a custom gene array focusing on T-regulatory cell processes. The two genes that were differentially expressed in every comparison were TGF beta and RNASEN with very low expression in the rejector group. The prolonged non-adherent group had the maximum expression for TGF beta but average RNASEN expression as compared to the low expression for rejectors and high for post-5 years patients. The patients presented survived for varying lengths of time without immunosuppression. The gene array analysis showed intriguing differences between these rare patients and important patient cohorts. Further efforts should be directed to finding and studying more patients who survive despite lack of prescribed immunosuppression. The mechanisms underlying this phenomenon may inform future advances in transplant immunosuppression.
Collapse
Affiliation(s)
| | - Prakash Rao
- New Jersey Sharing Network, New Providence, NJ, USA
| | - Dayanand Deo
- New Jersey Sharing Network, New Providence, NJ, USA
| | | |
Collapse
|
4
|
DiVita M, Visveswaran GK, Makam K, Naji P, Cohen M, Kapoor S, Saunders CR, Zucker MJ. Emergent TandemHeart-ECMO for acute severe mitral regurgitation with cardiogenic shock and hypoxaemia: a case series. Eur Heart J Case Rep 2020; 4:1-6. [PMID: 32128490 PMCID: PMC7047057 DOI: 10.1093/ehjcr/ytz234] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/20/2019] [Accepted: 12/04/2019] [Indexed: 11/17/2022]
Abstract
Background Acute severe mitral regurgitation (MR) associated with cardiogenic shock is a life-threatening emergency. Traditional teaching has focused on the need for emergent coronary angiography and/or intra-aortic balloon counterpulsation in preparation for emergent open-heart surgery for repair/replacement. Unfortunately, emergent open-heart surgery in patients with acute MR complicated by cardiogenic shock is associated with 25–46% perioperative mortality. New devices have provided additional options for stabilization prior to emergent surgery which facilitate improved outcomes. Case summary We present two cases of acute severe MR resulting in cardiogenic shock and profound hypoxaemia. TandemHeart® mechanical circulatory support with an oxygenator spliced into the circuit, akin to veno-arterial extracorporeal membrane oxygenation (ECMO), facilitated haemodynamic stabilization and decongestion of the lungs facilitating successful bridge to mitral valve surgery. Successful discharge to home was achieved in both patients with good neurological outcomes and sustained long-term functional recovery at 18 and 14 months, respectively. Discussion Selective use of the TandemHeart®, with or without ECMO, facilitates management of the critically ill cardiogenic shock patient with acute severe MR.
Collapse
Affiliation(s)
- Michael DiVita
- Department of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| | - Gautam K Visveswaran
- Department of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| | - Kasaiah Makam
- Department of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| | - Peyman Naji
- Department of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| | - Marc Cohen
- Department of Cardiology, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| | - Saurabh Kapoor
- Department of Heart Failure and Transplant, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| | - Craig R Saunders
- Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| | - Mark J Zucker
- Department of Heart Failure and Transplant, Newark Beth Israel Medical Center, 201 Lyons Ave, Newark, NJ 07112, USA
| |
Collapse
|
5
|
Guglin M, Zucker MJ, Bazan VM, Bozkurt B, El Banayosy A, Estep JD, Gurley J, Nelson K, Malyala R, Panjrath GS, Zwischenberger JB, Pinney SP. Venoarterial ECMO for Adults. J Am Coll Cardiol 2019; 73:698-716. [DOI: 10.1016/j.jacc.2018.11.038] [Citation(s) in RCA: 188] [Impact Index Per Article: 37.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2018] [Revised: 10/03/2018] [Accepted: 11/14/2018] [Indexed: 02/05/2023]
|
6
|
Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, Tsai EJ, Hilfiker-Kleiner D, Kamiya CA, Mazzarotto F, Cook SA, Halder I, Prasad SK, Pisarcik J, Hanley-Yanez K, Alharethi R, Damp J, Hsich E, Elkayam U, Sheppard R, Kealey A, Alexis J, Ramani G, Safirstein J, Boehmer J, Pauly DF, Wittstein IS, Thohan V, Zucker MJ, Liu P, Gorcsan J, McNamara DM, Seidman CE, Seidman JG, Arany Z. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med 2016; 374:233-41. [PMID: 26735901 PMCID: PMC4797319 DOI: 10.1056/nejmoa1505517] [Citation(s) in RCA: 365] [Impact Index Per Article: 45.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Background Peripartum cardiomyopathy shares some clinical features with idiopathic dilated cardiomyopathy, a disorder caused by mutations in more than 40 genes, including TTN, which encodes the sarcomere protein titin. Methods In 172 women with peripartum cardiomyopathy, we sequenced 43 genes with variants that have been associated with dilated cardiomyopathy. We compared the prevalence of different variant types (nonsense, frameshift, and splicing) in these women with the prevalence of such variants in persons with dilated cardiomyopathy and with population controls. Results We identified 26 distinct, rare truncating variants in eight genes among women with peripartum cardiomyopathy. The prevalence of truncating variants (26 in 172 [15%]) was significantly higher than that in a reference population of 60,706 persons (4.7%, P=1.3×10(-7)) but was similar to that in a cohort of patients with dilated cardiomyopathy (55 of 332 patients [17%], P=0.81). Two thirds of identified truncating variants were in TTN, as seen in 10% of the patients and in 1.4% of the reference population (P=2.7×10(-10)); almost all TTN variants were located in the titin A-band. Seven of the TTN truncating variants were previously reported in patients with idiopathic dilated cardiomyopathy. In a clinically well-characterized cohort of 83 women with peripartum cardiomyopathy, the presence of TTN truncating variants was significantly correlated with a lower ejection fraction at 1-year follow-up (P=0.005). Conclusions The distribution of truncating variants in a large series of women with peripartum cardiomyopathy was remarkably similar to that found in patients with idiopathic dilated cardiomyopathy. TTN truncating variants were the most prevalent genetic predisposition in each disorder.
Collapse
Affiliation(s)
- James S Ware
- From the Department of Genetics, Harvard Medical School (J.S.W., E.M., C.M.Y., C.E.S., J.G.S.), the Howard Hughes Medical Institute (C.E.S.), and the Cardiovascular Division, Brigham and Women's Hospital (J.S.W., E.M., C.E.S., J.G.S.) - all in Boston; the Cardiovascular Institute and the Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia (J.L., T.D., T.P.C., Z.A.), the Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh (I.H., J.P., K.H.-Y., J.G., D.M.M.), and Penn State Hershey Medical Center, Hershey (J.B.) - all in Pennsylvania; the National Institute for Health Research Royal Brompton Cardiovascular Biomedical Research Unit (J.S.W., F.M., S.K.P.) and the National Heart and Lung Institute (J.S.W., F.M., S.A.C., S.K.P.), Imperial College London, London; the Division of Cardiology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York (E.J.T.), and the University of Rochester, Rochester (J.A.) - both in New York; the Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany (D.H.-K.); the Department of Perinatology and Gynecology, the National Cerebral and Cardiovascular Center, Osaka, Japan (C.A.K.); the National Heart Center and Duke-National University of Singapore, Singapore (S.A.C.); the Intermountain Medical Center, Murray, Utah (R.A.); Vanderbilt University, Nashville (J.D.); Cleveland Clinic, Cleveland (E.H.); University of Southern California, Los Angeles (U.E.); McGill University and Jewish General Hospital, Montreal (R.S.), University of Calgary, Calgary, AB (A.K.), and University of Toronto, Toronto (P.L.) - all in Canada; University of Maryland, College Park (G.R.), and Johns Hopkins Hospital, Baltimore (I.S.W.) - both in Maryland; Morristown Hospital, Morristown (J.S.), and Newark Beth Israel Medical Center, Newark (M.J.Z.) - both in New Jersey; Truman Medical Center, University of Missouri, Kansas City (D.F.P.); and Wa
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Chauhan D, Karanam AB, Merlo A, Tom Bozzay PA, Zucker MJ, Seethamraju H, Shariati N, Russo MJ. Post-transplant survival in idiopathic pulmonary fibrosis patients concurrently listed for single and double lung transplantation. J Heart Lung Transplant 2016; 35:657-60. [PMID: 26856664 DOI: 10.1016/j.healun.2015.12.030] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2014] [Revised: 11/04/2015] [Accepted: 12/15/2015] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Lung transplantation is a widely accepted treatment for patients with end-stage lung disease related to idiopathic pulmonary fibrosis (IPF). However, there are conflicting data on whether double lung transplant (DLT) or single lung transplant (SLT) is the superior therapy in these patients. The purpose of this study was to determine whether actuarial post-transplant graft survival among IPF patients concurrently listed for DLT and SLT is greater for recipients undergoing the former or the latter. METHODS The United Network for Organ Sharing provided de-identified patient-level data. Analysis included lung transplant candidates with IPF listed between January 1, 2001 and December 31, 2009 (n = 3,411). The study population included 1,001 (29.3%) lung transplant recipients concurrently listed for DLT and SLT, all ≥18 years of age. The primary outcome measure was actuarial post-transplant graft survival, expressed in years. RESULTS Among the study population, 433 (43.26%) recipients underwent SLT and 568 (56.74%) recipients underwent DLT. The analysis included 2,722.5 years at risk, with median graft survival of 5.31 years. On univariate (p = 0.317) and multivariate (p = 0.415) regression analyses, there was no difference in graft survival between DLT and SLT. CONCLUSIONS Among IPF recipients concurrently listed for DLT and SLT, there is no statistical difference in actuarial graft survival between recipients undergoing DLT vs SLT. This analysis suggests that increased use of SLT for IPF patients may increase the availability of organs to other candidates, and thus increase the net benefit of these organs, without measurably compromising outcomes.
Collapse
Affiliation(s)
- Dhaval Chauhan
- Department of Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey; Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey.
| | - Ashwin B Karanam
- Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey; Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey
| | - Aurelie Merlo
- Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey
| | - P A Tom Bozzay
- Division of Pediatric and Congenital Cardiothoracic Surgery, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Mark J Zucker
- Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey
| | - Harish Seethamraju
- Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey
| | - Nazly Shariati
- Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey
| | - Mark J Russo
- Department of Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey; Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey; Newark Beth Israel Medical Center, Barnabas Heart Hospitals, Newark, New Jersey
| |
Collapse
|
8
|
Visveswaran GK, Gidea C, Baran D, Cohen M, Zucker MJ. Acute left ventricular dysfunction complicating pregnancy on ECMO: Tri-iodothyronine to the rescue with real time transesophageal echocardiography. J Cardiol Cases 2015; 13:33-36. [PMID: 30546606 DOI: 10.1016/j.jccase.2015.09.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2015] [Revised: 08/16/2015] [Accepted: 09/29/2015] [Indexed: 11/28/2022] Open
Abstract
Cardiac dysfunction is a common accompaniment to severe sepsis. Clinical management of the same complicating pregnancy presents unique challenges balancing maternal and fetal well-being. Can short-term intravenous (IV) tri-iodothyronine (T3) be used in the management of these patients? T3 has been reported in varied clinical settings to favorably affect cardiac lusitropy, inotropy, and chronotropy without significant side effects. We report a case of acute severe left ventricular dysfunction in a pregnant woman with severe acute respiratory distress syndrome on veno-venous extracorporeal membrane oxygenation managed with short-term IV T3. Hemodynamic stability was rapidly achieved and the improvement in contractility imaged in real time by transesophageal echocardiography. <Learning objective: Tri-iodothyronine (T3) rapidly affects cardiac inotropy, lusitropy, chronotropy, and systemic vascular resistance. Widespread application of intravenous T3 for treatment of heart failure is currently limited by a paucity of scientific literature. Selective short-term intravenous T3 use is an underutilized adjunct in the management of acute left ventricular dysfunction.>.
Collapse
Affiliation(s)
| | - Claudia Gidea
- Heart Failure Treatment and Transplant Program, Newark Beth Israel Medical Center, Newark, NJ, USA
| | - David Baran
- Heart Failure Treatment and Transplant Program, Newark Beth Israel Medical Center, Newark, NJ, USA
| | - Marc Cohen
- Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA
| | - Mark J Zucker
- Heart Failure Treatment and Transplant Program, Newark Beth Israel Medical Center, Newark, NJ, USA
| |
Collapse
|
9
|
Lo SC, Hung GC, Li B, Lei H, Li T, Nagamine K, Tsai S, Zucker MJ, Olesnicky L. Mixed group of Rhizobiales microbes in lung and blood of a patient with fatal pulmonary illness. Int J Clin Exp Pathol 2015; 8:13834-13852. [PMID: 26823697 PMCID: PMC4713483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/28/2015] [Accepted: 10/28/2015] [Indexed: 06/05/2023]
Abstract
We examined the microbial composition in the diseased lung and early-phase microbial cultures from the blood of a patient with a rapidly progressing fatal pulmonary illness. Although no microbes could be isolated from such cultures during the initial study, the HTS-microbiome study revealed the presence of a unique mixture of alphaproteobacteria, composed mainly of different families of Rhizobiales microbes. Microbial 16S rDNA sequences matching closely to Afipia cberi were identified mainly in the patient's diseased lung tissue, but only rarely in the early-phase blood cultures. Conversely, the high abundance of sequences found in early-phase blood cultures of different broth media matched closely with those of the families Methylobacteriaceae, Phyllobacteriaceae and Sphingomonadaceae. The two species that successfully adapted to grow in a laboratory culture system were A. cberi and Mesorhizobium hominis, which eventually were isolated from a previously cryopreserved blood culture of SP4 broth. Many other species, including members of the Bradyrhizobiaceae and Phyllobacteriaceae families, and all members of the Methylobacteriaceae and Sphingomonadaceae families identified by HTS remained non-cultivated. We developed specific PCR primers and FISH probes, which detected the target Rhizobiales microbes in former blood cultures and autopsy lung tissues. It is unclear what role these Rhizobiales microbes might have played in the patient's complex disease process. However, the above mentioned assays should help in rapidly detecting and identifying these previously unrecognized Rhizobiales microbes in patients.
Collapse
Affiliation(s)
- Shyh-Ching Lo
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug AdministrationSilver Spring, Maryland 20993, USA
| | - Guo-Chiuan Hung
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug AdministrationSilver Spring, Maryland 20993, USA
| | - Bingjie Li
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug AdministrationSilver Spring, Maryland 20993, USA
| | - Haiyan Lei
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug AdministrationSilver Spring, Maryland 20993, USA
| | - Tianwei Li
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug AdministrationSilver Spring, Maryland 20993, USA
| | - Kenjiro Nagamine
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug AdministrationSilver Spring, Maryland 20993, USA
| | - Shien Tsai
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug AdministrationSilver Spring, Maryland 20993, USA
| | - Mark J Zucker
- Department of Medicine, Newark Beth Israel Medical CenterNewark, New Jersey 07112, USA
| | - Ludmilla Olesnicky
- Department of Pathology, Newark Beth Israel Medical CenterNewark, New Jersey 07112, USA
| |
Collapse
|
10
|
Jaiswal A, Sabnani I, Baran DA, Zucker MJ. A unique case of rituximab-related posterior reversible encephalopathy syndrome in a heart transplant recipient with posttransplant lymphoproliferative disorder. Am J Transplant 2015; 15:823-6. [PMID: 25648447 DOI: 10.1111/ajt.13021] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 09/04/2014] [Accepted: 09/06/2014] [Indexed: 01/25/2023]
Abstract
Rituximab is commonly used as a first line therapy to treat posttransplant lymphoproliferative disorders (PTLDs). It has also proved useful in the management of refractory antibody mediated graft rejection. We report an unusual case in which a heart transplant recipient being treated with rituximab for PTLD developed altered mental status, hallucinations and visual symptoms and magnetic resonance imaging (MRI) findings of symmetrical enhancement suggestive of posterior reversible leukoencephalopathy syndrome (PRES). Resolution of these clinical symptoms and radiological findings after discontinuation of therapy confirmed the diagnosis. This is the first case of PRES seen due to rituximab in a heart transplant recipient. Another unique feature of the case is the development of PRES after second cycle of rituximab as compared to prior reports in nonheart transplant patients in which the syndrome developed after first dose administration. The objective of this case report is to increase the awareness of this rare entity amongst immunocompromised transplant patients.
Collapse
Affiliation(s)
- A Jaiswal
- Tulane University Heart and Vascular Institute, New Orleans, LA
| | | | | | | |
Collapse
|
11
|
Meyer DM, Rogers JG, Edwards LB, Callahan ER, Webber SA, Johnson MR, Vega JD, Zucker MJ, Cleveland JC. The future direction of the adult heart allocation system in the United States. Am J Transplant 2015; 15:44-54. [PMID: 25534445 DOI: 10.1111/ajt.13030] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Revised: 07/22/2014] [Accepted: 07/22/2014] [Indexed: 01/25/2023]
Abstract
Ensuring equitable and fair organ allocation is a central charge of the United Network for Organ Sharing (UNOS) as the Organ Procurement and Transplantation Network (OPTN) through its contract with the Department of Health and Human Services (DHHS). The OPTN/UNOS Board initiated a reassessment of the current allocation system. This paper describes the efforts of the OPTN/UNOS Heart Subcommittee, acting on behalf of the OPTN/UNOS Thoracic Organ Transplantation Committee, to modify the current allocation system. The Subcommittee assessed the limitations of the current three-tiered system, outcomes of patients with status exceptions, emerging ventricular assist device (VAD) population, options for improved geographic sharing and status of potentially disenfranchised groups. They analyzed waiting list and posttransplant mortality rates of a contemporary cohort of patient groups at risk, in collaboration with the Scientific Registry of Transplant Recipients to develop a proposed multi-tiered allocation scheme. This proposal provides a framework for simulation modeling to project whether candidates would have better waitlist survival in the revised allocation system, and whether posttransplant survival would remain stable. The tiers are subject to change, based on further analysis by the Heart Subcommittee and will lead to the development of a more effective and equitable heart allocation system.
Collapse
Affiliation(s)
- D M Meyer
- Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Russo MJ, Gidea C, Karanam R, Baran D, Saunders CR, Zucker MJ, Camacho MT. Successful Management of Thrombosis of the Proximal Aorta after Implantation with a Biventricular Assist Device. J Extra Corpor Technol 2014; 46:310-313. [PMID: 26357801 PMCID: PMC4557476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/18/2014] [Accepted: 10/02/2014] [Indexed: 06/05/2023]
Abstract
Continuous-flow ventricular assist devices (CVADs) are associated with a significant complication profile that includes thrombosis of the ascending aorta and aortic valve, thromboembolism, and stroke. Despite an increasing number of reports of thromboembolic complications related to CVADs, there is little in the literature to guide their management. This report describes successful management strategies used during two cases of thrombosis of the ascending aorta during biventricular CentriMag (Levitronix LLC, Waltham, MA) support, including using pre-existing cannulas to initiate cardiopulmonary bypass.
Collapse
Affiliation(s)
- Mark J. Russo
- Heart and Lung Transplant Center, Newark Beth Israel Medical Center, Newark, New Jersey
- Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey
- Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, New Jersey
| | - Claudia Gidea
- Heart and Lung Transplant Center, Newark Beth Israel Medical Center, Newark, New Jersey
| | - Ravi Karanam
- Heart and Lung Transplant Center, Newark Beth Israel Medical Center, Newark, New Jersey
- Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey
- Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, New Jersey
| | - David Baran
- Heart and Lung Transplant Center, Newark Beth Israel Medical Center, Newark, New Jersey
| | - Craig R. Saunders
- Heart and Lung Transplant Center, Newark Beth Israel Medical Center, Newark, New Jersey
- Cardiovascular Clinical Research Unit, Barnabas Heart Hospitals, Newark, New Jersey
- Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, New Jersey
| | - Mark J. Zucker
- Heart and Lung Transplant Center, Newark Beth Israel Medical Center, Newark, New Jersey
| | - Margarita T. Camacho
- Heart and Lung Transplant Center, Newark Beth Israel Medical Center, Newark, New Jersey
- Department of Cardiothoracic Surgery, Newark Beth Israel Medical Center, Newark, New Jersey
| |
Collapse
|
13
|
Lo SC, Li B, Hung GC, Lei H, Li T, Zhang J, Nagamine K, Tsai S, Zucker MJ, Olesnicky L. Isolation and characterization of two novel bacteria Afipia cberi and Mesorhizobium hominis from blood of a patient afflicted with fatal pulmonary illness. PLoS One 2013; 8:e82673. [PMID: 24367538 PMCID: PMC3867388 DOI: 10.1371/journal.pone.0082673] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Accepted: 10/25/2013] [Indexed: 11/18/2022] Open
Abstract
We recently isolated and discovered new Bradyrhizobiaceae microbes from the cryopreserved culture broth of blood samples from 3 patients with poorly defined illnesses using modified SP4 media and culture conditions coupled with genomic sequencing. Using a similar protocol, we studied a previously cryopreserved culture broth of blood sample from a patient who had succumbed to an acute onset of fulminant pulmonary illness. We report that two phases of microbial growth were observed in the re-initiated culture. Biochemical and genomic characterization revealed microbes isolated from the first phase of growth were new Afipia species of Bradyrhizobiaceae, tentatively named A. cberi with a ~ 5 MB chromosome that was different from those of all previously known Afipia microbes including the newly discovered A. septicemium. The microbes isolated from the second phase of growth were prominent sugar assimilators, novel Phyllobacteriaceae, phylogenetically most closely related to Mesorhizobium and tentatively named M. hominis with a ~ 5.5 MB chromosome. All A. cberi isolates carry a circular ~ 140 KB plasmid. Some M. hominis isolates possess a circular ~ 412 KB plasmid that can be lost in prolonged culture or passage. No antibiotics resistant genes could be identified in both of the A. cberi and M. hominis plasmids. Antibiotic susceptibility studies using broth culture systems revealed isolates of A. cberi could be sensitive to some antibiotics, but all isolates of M. hominis were resistant to essentially all tested antibiotics. However, the cell-free antibiotics susceptibility test results may not be applicable to clinical treatment against the microbes that are known to be capable of intracellular growth. It remains to be determined if the 2 previously unknown Rhizobiales were indeed pathogenic and played a role in the pulmonary disease process in this patient. Specific probes and methods will be developed to re-examine the diseased lungs from patient's autopsy.
Collapse
Affiliation(s)
- Shyh-Ching Lo
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
- * E-mail:
| | - Bingjie Li
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
| | - Guo-Chiuan Hung
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
| | - Haiyan Lei
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
| | - Tianwei Li
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
| | - Jing Zhang
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
| | - Kenjiro Nagamine
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
| | - Shien Tsai
- Tissue Microbiology Laboratory, Division of Cellular and Gene Therapies, Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, United States of America
| | - Mark J. Zucker
- Department of Medicine, Newark Beth Israel Medical Center, Newark, New Jersey, United States of America
| | - Ludmilla Olesnicky
- Department of Pathology, Newark Beth Israel Medical Center, Newark, New Jersey, United States of America
| |
Collapse
|
14
|
Boehmer JP, Starling RC, Cooper LT, Torre-Amione G, Wittstein I, Dec GW, Markham DW, Zucker MJ, Gorcsan J, McTiernan C, Kip K, McNamara DM. Left Ventricular Assist Device Support and Myocardial Recovery in Recent Onset Cardiomyopathy. J Card Fail 2012; 18:755-61. [DOI: 10.1016/j.cardfail.2012.08.001] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Revised: 07/19/2012] [Accepted: 08/03/2012] [Indexed: 10/27/2022]
|
15
|
Redeker NS, Adams L, Berkowitz R, Blank L, Freudenberger R, Gilbert M, Walsleben J, Zucker MJ, Rapoport D. Nocturia, sleep and daytime function in stable heart failure. J Card Fail 2012; 18:569-75. [PMID: 22748491 PMCID: PMC3389347 DOI: 10.1016/j.cardfail.2012.05.002] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Revised: 05/01/2012] [Accepted: 05/04/2012] [Indexed: 11/19/2022]
Abstract
BACKGROUND The aim of this study was to evaluate nocturia severity and nocturia-related differences in sleep, daytime symptoms and functional performance among patients with stable heart failure (HF). METHODS AND RESULTS In this cross-sectional observational study, we recruited 173 patients [mean age 60.3 ± 16.8 years; female n = 60 (35%); mean left ventricular ejection fraction 32 ± 14.6%] with stable chronic HF from HF disease management programs in the northeastern United States. Participants reported nocturia and completed a 6-minute walk test (6MWT), 1 night of ambulatory polysomnography, and the SF-36 Medical Outcomes Study, Epworth Sleepiness, Pittsburgh Sleep Quality Index, Multidimensional Assessment of Fatigue, and Centers for the Epidemiological Studies of Depression scales. Participants reported 0 (n = 30; 17.3%), 1-2 (n = 87; 50.2%), and ≥3 (n = 56; 32.4%) nightly episodes of nocturia. There were decreases in sleep duration and efficiency, REM and stage 3-4 sleep, physical function, and 6MWT distance and increases in the percentage of wake time after sleep onset, insomnia symptoms, fatigue, and sleepiness across levels of nocturia severity. CONCLUSIONS Nocturia is common, severe, and closely associated with decrements in sleep and functional performance and increases in fatigue and sleepiness in patients with stable HF.
Collapse
Affiliation(s)
- Nancy S Redeker
- Yale University School of Nursing, 100 Church Street South, New Haven, CT 06536-07040, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Jessup M, Albert NM, Lanfear DE, Lindenfeld J, Massie BM, Walsh MN, Zucker MJ. ACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation. J Card Fail 2011; 17:349-58. [DOI: 10.1016/j.cardfail.2011.04.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
17
|
Potapov E, Meyer D, Swaminathan M, Ramsay M, El Banayosy A, Diehl C, Veynovich B, Gregoric ID, Kukucka M, Gromann TW, Marczin N, Chittuluru K, Baldassarre JS, Zucker MJ, Hetzer R. Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial. J Heart Lung Transplant 2011; 30:870-8. [PMID: 21530317 DOI: 10.1016/j.healun.2011.03.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2010] [Revised: 02/23/2011] [Accepted: 03/02/2011] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND Used frequently for right ventricular dysfunction (RVD), the clinical benefit of inhaled nitric oxide (iNO) is still unclear. We conducted a randomized, double-blind, controlled trial to determine the effect of iNO on post-operative outcomes in the setting of left ventricular assist device (LVAD) placement. METHODS Included were 150 patients undergoing LVAD placement with pulmonary vascular resistance ≥ 200 dyne/sec/cm(-5). Patients received iNO (40 ppm) or placebo (an equivalent concentration of nitrogen) until 48 hours after separation from cardiopulmonary bypass, extubation, or upon meeting study-defined RVD. For ethical reasons, crossover to open-label iNO was allowed during the 48-hour treatment period if RVD criteria were met. RESULTS RVD criteria were met by 7 of 73 patients (9.6%; 95% confidence interval, 2.8-16.3) in the iNO group compared with 12 of 77 (15.6%; 95% confidence interval, 7.5-23.7) who received placebo (p = 0.330). Time on mechanical ventilation decreased in the iNO group (median days, 2.0 vs 3.0; p = 0.077), and fewer patients in the iNO group required an RVAD (5.6% vs 10%; p = 0.468); however, these trends did not meet statistical boundaries of significance. Hospital stay, intensive care unit stay, and 28-day mortality rates were similar between groups, as were adverse events. Thirty-five patients crossed over to open-label iNO (iNO, n = 15; placebo, n = 20). Eighteen patients (iNO, n = 9; placebo, n = 9) crossed over before RVD criteria were met. CONCLUSIONS Use of iNO at 40 ppm in the perioperative phase of LVAD implantation did not achieve significance for the primary end point of reduction in RVD. Similarly, secondary end points of time on mechanical ventilation, hospital or intensive care unit stay, and the need for RVAD support after LVAD placement were not significantly improved.
Collapse
|
18
|
Jessup M, Albert NM, Lanfear DE, Lindenfeld J, Massie BM, Walsh MN, Zucker MJ. ACCF/AHA/HFSA 2011 survey results: current staffing profile of heart failure programs, including programs that perform heart transplant and mechanical circulatory support device implantation: a report of the ACCF Heart Failure and Transplant Committee, AHA Heart Failure and Transplantation Committee, and Heart Failure Society of America. Circ Heart Fail 2011; 4:378-87. [PMID: 21464151 DOI: 10.1161/hhf.0b013e3182186210] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
OBJECTIVES There have been no published recommendations about staffing needs for a heart failure (HF) clinic or an office setting focused on heart transplant. The goal of this survey was to understand the current staffing environment of HF, transplant, and mechanical circulatory support device (MCSD) programs in the United States and abroad. This report identifies current staffing patterns but does not endorse a particular staffing model. METHODS An online survey, jointly sponsored by the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), and the Heart Failure Society of America (HFSA), was sent to the members of all 3 organizations who had identified themselves as interested in HF, heart transplant, or both, between March 12, 2009, and May 12, 2009. RESULTS The overall response rate to the 1823 e-mail surveys was 23%. There were 257 unique practices in the United States (81% of total sites) and 58 international sites (19%); approximately 30% of centers were in a cardiovascular group practice and 30% in a medical school hospital setting. The large majority of practices delivered HF care in both an inpatient and outpatient environment, and slightly more centers were implanting MCSDs (47%) than performing cardiac transplantation (39%). Most practices (43%) were small, with <4 staff members, or small- to medium-sized (34%), with 4 to 10 staff members, with only 23% being medium (11-20 staff) or large programs (>20 staff). On average, a US HF practice cared for 1641 outpatients annually. An average HF program with transplant performed 10 transplants. Although larger programs were able to perform more transplants and see more outpatient HF visits, their clinician staffing volume tended to double for approximately every 500 to 700 additional HF visits annually. The average staffing utilization was 2.65 physician full-time equivalents (FTEs), 2.21 nonphysician practitioner (nurse practitioner or physician assistant) FTEs, and 2.61 nurse coordinator FTEs annually. CONCLUSIONS The HF patient population is growing in number in the United States and internationally, and the clinicians who provide the highly skilled and time-consuming care to this population are under intense scrutiny as a result of focused quality improvement initiatives and reduced financial resources. Staffing guidelines should be developed to ensure that an adequate number of qualified professionals are hired for a given practice volume. These survey results are an initial step in developing such standards.
Collapse
|
19
|
Baran DA, Zucker MJ, Arroyo LH, Camacho M, Goldschmidt ME, Nicholls SJ, Prevost-Fernandez J, Carr C, Adams L, Pardi S, Hou V, Binetti M, McCahill J, Chichetti J, Viloria V, SanAgustin MG, Ebuenga-Smith J, Mele L, Martin A, Blicharz D, Wolski K, Olesnicky L, Qian F, Gass AL, Cohen M. A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart Transplantation. Circ Heart Fail 2011; 4:129-37. [DOI: 10.1161/circheartfailure.110.958520] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- David A. Baran
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Mark J. Zucker
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Luis H. Arroyo
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Margarita Camacho
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Marc E. Goldschmidt
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Stephen J. Nicholls
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Jeanne Prevost-Fernandez
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Candace Carr
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Laura Adams
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Susan Pardi
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Vera Hou
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Maria Binetti
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Jeanine McCahill
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Joanne Chichetti
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Valerie Viloria
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Mary Gladys SanAgustin
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Jennifer Ebuenga-Smith
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Leslie Mele
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Anthony Martin
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Donna Blicharz
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Kathy Wolski
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Ludmilla Olesnicky
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Fang Qian
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Alan L. Gass
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| | - Marc Cohen
- From Newark Beth Israel Medical Center (D.A.B., M.J.Z., L.H.A., M.C., M.E.G., J.P.-F., C.C., L.A., S.P., V.H., M.B., J.M., J.C., V.V., M.G.S., J.E.-S., A.M., D.B., L.O., F.Q., M.C.), Newark, NJ; The Cleveland Clinic (S.J.N., K.W.), Cleveland, OH; and Westchester Medical Center (A.L.G.), Valhalla, NY
| |
Collapse
|
20
|
Redeker NS, Muench U, Zucker MJ, Walsleben J, Gilbert M, Freudenberger R, Chen M, Campbell D, Blank L, Berkowitz R, Adams L, Rapoport DM. Sleep disordered breathing, daytime symptoms, and functional performance in stable heart failure. Sleep 2010; 33:551-60. [PMID: 20394325 PMCID: PMC2849795 DOI: 10.1093/sleep/33.4.551] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
STUDY OBJECTIVES To evaluate characteristics of sleep disordered breathing (SDB); clinical and demographic correlates of SDB; and the extent to which SDB explains functional performance and symptoms in stable heart failure patients receiving care in structured HF disease management programs. DESIGN Cross-sectional, observational study. SETTING Structured heart failure disease management programs. PARTICIPANTS 170 stable chronic heart failure patients (mean age = 60.3 +/- 16.8 years; n = 60 [35%] female; n = 50 [29%] African American; left ventricular ejection fraction mean = 32 +/- 14.6). INTERVENTIONS N/A. MEASUREMENTS AND RESULTS Full polysomnography was obtained for one night on participants in their homes. Participants completed the 6-minute walk, 3 days of actigraphy, MOS-SF 36, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Multi-Dimensional Assessment of Fatigue Scale, and the Centers for the Epidemiological Studies of Depression Scale. Fifty-one percent had significant SDB; Sixteen (9%) of the total sample had central sleep apnea. Severe SDB was associated with a 4-fold increase in the likelihood of poor self-reported physical function (OR = 4.15, 95%CI = 1.19-14.57) and CSA was associated with low levels of daytime mobility (OR = 4.09, 95%CI = 1.23-13.62) after controlling for clinical and demographic variables. There were no statistically significant relationships between SDB and daytime symptoms or self-reported sleep, despite poorer objective sleep quality in patients with SDB. CONCLUSIONS Severe SDB is associated with poor physical function in patients with stable HF but not with daytime symptoms or self-reported sleep, despite poorer objective sleep quality in patients with SDB.
Collapse
|
21
|
Zucker MJ, Sabnani I, Baran DA, Balasubramanian S, Camacho M. Cardiac transplantation and/or mechanical circulatory support device placement using heparin anti-coagulation in the presence of acute heparin-induced thrombocytopenia. J Heart Lung Transplant 2009; 29:53-60. [PMID: 19819167 DOI: 10.1016/j.healun.2009.08.016] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2009] [Revised: 08/07/2009] [Accepted: 08/09/2009] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Patients with congestive heart failure, decreased left ventricular function, and debilitation are frequently maintained on anti-coagulants, including heparin. As such, these patients are at high risk for developing heparin-induced thrombocytopenia (HIT). Some of these HIT-positive individuals will ultimately undergo urgent heart transplantation or placement of a mechanical circulatory support device (MCSD). Such procedures require cardiopulmonary bypass (CPB) and full anti-coagulation. The safety of re-exposure to heparin during CPB despite the presence of recent-onset thrombocytopenia and Hep/PF4 antibodies has not been studied in the transplant or MCSD populations. METHODS Over a 24-month period, 75 heart transplants and 55 MCSD implants were performed. Fourteen patients with acute HIT (thrombocytopenia and positive Hep/PF4 antibody by enzyme-linked immunosorbent assay [ELISA]) and 3 patients with a history of remote HIT underwent cardiac transplantation (n = 9) and/or MCSD placement (n = 8) using heparin as the anti-coagulant during CPB. The median time from diagnosis to CPB was 4.5 days in patients with acute HIT. RESULTS Thirty-day survival was 100% in transplant patients and 75% in MCSD patients. Post-transplant ELISA testing was found to be negative in 4 patients with acute HIT and 3 with remote HIT. CONCLUSIONS This series demonstrates that short-term re-exposure to heparin during urgent CPB for heart transplantation or MCSD placement is safe despite the presence of thrombocytopenia and Hep/PF4 antibodies. Moreover, the rapid clearance of Hep/PF4 antibodies in our transplant patients suggests a potential therapeutic role for immunosuppressive therapy in the management of HIT in the acute setting.
Collapse
Affiliation(s)
- Mark J Zucker
- Division of Cardiology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA.
| | | | | | | | | |
Collapse
|
22
|
Meyns B, Klotz S, Simon A, Droogne W, Rega F, Griffith B, Dowling R, Zucker MJ, Burkhoff D. Proof of concept: hemodynamic response to long-term partial ventricular support with the synergy pocket micro-pump. J Am Coll Cardiol 2009; 54:79-86. [PMID: 19555845 DOI: 10.1016/j.jacc.2009.04.023] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2009] [Revised: 04/03/2009] [Accepted: 04/06/2009] [Indexed: 12/22/2022]
Abstract
OBJECTIVES The purpose of this study was to test the hemodynamic effects of partial ventricular support in patients with advanced heart failure. BACKGROUND The use of current left ventricular assist devices (VADs) that provide full circulatory support is restricted to critically ill patients because of associated risks. Smaller, less-invasive devices could expand VAD use to a larger pool of less-sick patients but would pump less blood, providing only partial support. METHODS The Synergy Pocket Micro-pump device (CircuLite, Inc., Saddle Brook, New Jersey) pumps approximately 3.0 l/min, is implanted (off pump) via a mini-thoracotomy, and is positioned in a right subclavicular subcutaneous pocket (like a pacemaker). The inflow cannula inserts into the left atrium; the outflow graft connects to the right subclavian artery. RESULTS A total of 17 patients (14 men), age 53 +/- 9 years with ejection fraction 21 +/- 6%, mean arterial pressure 73 +/- 7 mm Hg, pulmonary capillary wedge pressure 29 +/- 6 mm Hg, and cardiac index 1.9 +/- 0.4 l/min/m(2) received an implant. Duration of support ranged from 6 to 213 (median 81) days. In addition to demonstration of significant acute hemodynamic improvements in the first day of support, 9 patients underwent follow-up right heart catheterization at 10.6 +/- 6 weeks. These patients showed significant increases in arterial pressure (67 +/- 8 mm Hg vs. 80 +/- 9 mm Hg, p = 0.01) and cardiac index (2.0 +/- 0.4 l/min/m(2) vs. 2.8 +/- 0.6 l/min/m(2), p = 0.01) with large reductions in pulmonary capillary wedge pressure (30 +/- 5 mm Hg vs. 18 +/- 5 mm Hg, p = 0.001). CONCLUSIONS Partial support appears to interrupt the progressive hemodynamic deterioration typical of late-stage heart failure. If proven safe and durable, this device could be used in a relatively large population of patients with severe heart failure who are not sick enough to justify use of currently available full support VADs. (Safety and Performance Evaluation of CircuLite Synergy; NCT00878527).
Collapse
|
23
|
Baran DA, Zucker MJ, Arroyo LH, Alwarshetty MM, Ramirez MR, Prendergast TW, Goldstein DJ, Camacho M, Gass AL, Carr C, Cohen M. Randomized Trial of Tacrolimus Monotherapy: Tacrolimus In Combination, Tacrolimus Alone Compared (The TICTAC Trial). J Heart Lung Transplant 2007; 26:992-7. [DOI: 10.1016/j.healun.2007.07.022] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2007] [Revised: 06/22/2007] [Accepted: 07/15/2007] [Indexed: 10/22/2022] Open
|
24
|
Parsonnet V, Marak MJ, Panken E, Zucker MJ, Villanueva A, Kucher T, Driller J, Tuder G, Olesnicky L, Combs W. Detection of early renal transplant rejection by minimally-invasive monitoring of impedance variability. Biosens Bioelectron 2007; 22:2749-53. [DOI: 10.1016/j.bios.2006.10.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2006] [Revised: 09/19/2006] [Accepted: 10/23/2006] [Indexed: 11/26/2022]
|
25
|
Abstract
This article examines the Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients data on heart and lung transplantation in the United States from 1996 to 2005. The number of heart transplants performed and the size of the heart waiting list continued to drop, reaching 2126 and 1334, respectively, in 2005. Over the decade, post-transplant graft and patient survival improved, as did the chances for survival while on the heart waiting list. The number of deceased donor lung transplants increased by 78% since 1996, reaching 1407 in 2005 (up 22% from 2004). There were 3170 registrants awaiting lung transplantation at the end of 2005, down 18% from 2004. Death rates for both candidates and recipients have been dropping, as has the time spent waiting for a lung transplant. Other lung topics covered are living donation, recent surgical advances and changes in immunosuppression regimens. Heart-lung transplantation has declined to a small (33 procedures in 2005) but important need in the United States.
Collapse
Affiliation(s)
- E R Garrity
- University of Chicago Medical Center, Chicago, Illinois, USA.
| | | | | | | | | | | |
Collapse
|
26
|
Dellegrottaglie S, Einstein AJ, Sanz J, Zucker MJ, Fuster V, Rajagopalan S. Magnetic resonance imaging of a bioprosthetic mitral valve: a smiling heart. J Cardiovasc Med (Hagerstown) 2007; 8:394-5. [PMID: 17443112 DOI: 10.2459/01.jcm.0000268125.28672.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Santo Dellegrottaglie
- The Zena and Michael A. Wiener Cardiovascular Institute and The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, The Mount Sinai Medical Center, New York, New York 10029-6574, USA
| | | | | | | | | | | |
Collapse
|
27
|
Abstract
Large granular lymphocytic (LGL) leukemia is a rare disorder, usually caused by clonal proliferation of CD3+ CD57+ T-LGL cells. T-cell clonality is confirmed by rearrangements of the T-cell receptor (TCR) gene. Characteristic features of T-LGL leukemia include neutropenia, anemia, and constitutional symptoms such as fatigue. Many solid organ transplant recipients experience similar symptoms and have neutropenia and anemia often attributed to immunosuppressive therapy. The purpose of this study was to determine the prevalence of T-LGL proliferation in solid organ transplant recipients and demonstrate its association with leukopenia and anemia. Twenty-three cardiac and renal transplant patients were evaluated by peripheral smear examination, flow cytometry, and TCR gene rearrangement study by polymerase chain reaction. Ten of 14 (71%) cardiac transplant patients and 4 of 9 (44%) renal transplant patients, without evidence of either allograft rejection or a viral syndrome, were found to have clonal expansion of T-LGL cells. Constitutional symptoms were present in 30% of these patients. Anemia of <10 g/dL was seen in 75% of renal transplant and 10% of cardiac transplant patients. None of these patients had significant neutropenia defined as absolute neutrophil count of 1500 mu/L. Most of the patients did not require any specific therapeutic intervention. Although TCR gene rearrangement is considered a hallmark of T-LGL leukemia, we believe that this monoclonality is not a true form of posttransplant lymphoproliferative disorder. Constant antigenic stimulus from the allograft may be the underlying etiology of clonal expansion and may contribute to cytopenias and fatigue seen in transplant patients.
Collapse
Affiliation(s)
- I Sabnani
- Department of Oncology/Hematology, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
| | | | | | | |
Collapse
|
28
|
Lubitz SA, Baran DA, Alwarshetty MM, Zucker MJ, Arroyo LH, Chan M, Courtney MC, Correa R, Spielvogel D, Lansman SL, Gass AL. Improved Survival With Statins, Angiotensin Receptor Blockers, and Steroid Weaning After Heart Transplantation. Transplant Proc 2006; 38:1501-6. [PMID: 16797343 DOI: 10.1016/j.transproceed.2006.02.131] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2005] [Indexed: 11/26/2022]
Abstract
Various immunosuppressive and adjunctive pharmacological regimens exist for cardiac transplantation, though the associations between these regimens and long-term survival are unclear. We reviewed demographic, clinical, and pharmacological data from 220 consecutive adult heart transplant recipients between 1986 and 2003 who survived beyond 3 months. Immunosuppression was cyclosporine-based (n=94) or tacrolimus-based (n=126), and 104 patients were weaned off steroids (all receiving tacrolimus). Covariates of mortality were assessed in a Cox proportional hazards analysis. The mean age was 5.2+/-13 years. Survival was 96%, 88%, and 81% at 1, 3, and 5 years, respectively. Significant covariates associated with mortality included pretransplant diabetes mellitus (hazard ratio [HR] 2.83, 95% confidence interval [CI] 1.45 to 5.04), black race (HR 1.41, 95% CI 1.01 to 1.94), higher pretransplant creatinine clearance (HR 0.99, 95% CI 0.98 to 1.00), steroid withdrawal (HR 0.60, 95% CI 0.39 to 0.85), and exposure to a statin (HR 0.53, 95% CI 0.40 to 0.70) or an angiotensin receptor blocker (HR 0.50, 95% CI 0.20 to 0.95) after transplantation. Treatment with a statin, an angiotensin receptor blocker, and steroid withdrawal were each associated with improved survival in heart transplant recipients. These findings warrant prospective study, with specific emphasis on identifying the clinical effects of these medications in transplant recipients.
Collapse
Affiliation(s)
- S A Lubitz
- Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, New York, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Kobashigawa JA, Miller LW, Russell SD, Ewald GA, Zucker MJ, Goldberg LR, Eisen HJ, Salm K, Tolzman D, Gao J, Fitzsimmons W, First R. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6:1377-86. [PMID: 16686761 DOI: 10.1111/j.1600-6143.2006.01290.x] [Citation(s) in RCA: 256] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The most advantageous combination of immunosuppressive agents for cardiac transplant recipients has not yet been established. Between November 2001 and June 2003, 343 de novo cardiac transplant recipients were randomized to receive steroids and either tacrolimus (TAC) + sirolimus (SRL), TAC + mycophenolate mofetil (MMF) or cyclosporine (CYA) + MMF. Antilymphocyte induction therapy was allowed for up to 5 days. The primary endpoint of >/=3A rejection or hemodynamic compromise rejection requiring treatment showed no significant difference at 6 months (TAC/MMF 22.4%, TAC/SRL 24.3%, CYA/MMF 31.6%, p = 0.271) and 1 year (p = 0.056), but it was significantly lower in the TAC/MMF group when compared only to the CYA/MMF group at 1 year (23.4% vs. 36.8%; p = 0.029). Differences in the incidence of any treated rejection were significant (TAC/SRL = 35%, TAC/MMF = 42%, CYA/MMF = 59%; p < 0.001), as were median levels of serum creatinine (TAC/SRL = 1.5 mg/dL, TAC/MMF = 1.3 mg/dL, CYA/MMF = 1.5 mg/dL; p = 0.032) and triglycerides (TAC/SRL = 162 mg/dL, TAC/MMF = 126 mg/dL, CYA/MMF = 154 mg/dL; p = 0.028). The TAC/SRL group encountered fewer viral infections but more fungal infections and impaired wound healing. These secondary endpoints suggest that the TAC/MMF combination appears to offer more advantages than TAC/SRL or CYA/MMF in cardiac transplant patients, including fewer >/=3A rejections or hemodynamic compromise rejections and an improved side-effect profile.
Collapse
|
30
|
Mehra MR, Zucker MJ, Wagoner L, Michler R, Boehmer J, Kovarik J, Vasquez A. A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation. J Heart Lung Transplant 2005; 24:1297-304. [PMID: 16143248 DOI: 10.1016/j.healun.2004.09.010] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2004] [Revised: 09/05/2004] [Accepted: 09/22/2004] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND The role and pharmacokinetics of interleukin-2 (IL-2) monoclonal antibodies (mAbs) in heart transplantation remain unclear. This 1-year double-blind, randomized, placebo-controlled study evaluated safety, tolerability, and pharmacokinetics of the IL-2 mAb basiliximab with cyclosporine, mycophenolate mofetil, and steroids in adult de novo heart transplant recipients. METHODS Fifty-six patients received either basiliximab (20 mg) or placebo on Days 0 and 4 post-transplantation. Safety assessments included adverse events, serious adverse events, and infections. The time to and severity of biopsy-proven acute rejection (BPAR) were also assessed. RESULTS Basiliximab was generally well tolerated. There were no significant differences between treatment groups with respect to adverse event profiles, serious adverse events (84.0% vs 61.3%), or infections (84% vs 74.2%). The mean number of days to first BPAR was longer with basiliximab (73.7 +/- 59.68) than placebo (40.6 +/- 53.30) at 6 months, but not statistically significant (trend). The duration that basiliximab concentrations exceeded the CD25 saturation threshold averaged 38 +/- 13 days. Patients with rejection did not clear basiliximab faster or have shorter durations of saturation than rejection-free patients. None of the patients screened had detectable anti-idiotype antibodies. CONCLUSIONS These pilot results describe the pharmacokinetics of basiliximab and show that basiliximab appears to be tolerated with a similar safety profile to placebo in adult de novo heart transplant recipients. Larger scale clinical trials are feasible and warranted.
Collapse
Affiliation(s)
- Mandeep R Mehra
- Cardiomyopathy and Heart Transplant Center, Ochsner Clinic Foundation, New Orleans, Louisiana, USA.
| | | | | | | | | | | | | |
Collapse
|
31
|
Baran DA, Gass AL, Galin ID, Zucker MJ, Arroyo LH, Goldstein DJ, Prendergast T, Lubitz S, Courtney MC, Correa R, Chan M, Spielvogel D, Lansman SL. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. J Heart Lung Transplant 2005; 24:1886-90. [PMID: 16297796 DOI: 10.1016/j.healun.2005.03.010] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2004] [Revised: 03/11/2005] [Accepted: 03/11/2005] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Ventricular assist devices (VADs) are increasingly used to support critically ill heart failure patients awaiting transplantation. Previous work has focused on the Thoratec Heartmate VE device, use of which is associated with pre-formed antibody production. We reviewed our cumulative experience with the Worldheart Novacor VAD as a bridge to transplantation (BTT). METHODS From January 1989 through October 2002, 39 patients required a VAD bridge, with 26 of 39 surviving to transplantation. Antibody levels were assessed by complement-dependent cytotoxicity assay at routine intervals and expressed as panel reactive antibody (PRA) levels. Post-transplant allograft rejection, coronary vasculopathy, and survival were compared between Novacor-supported patients and non-VAD transplant recipients. RESULTS PRA values did not significantly change after VAD implantation (12.4% +/- 11.2% vs 14.8% +/- 12.3%, p = 0.28). Survival for the BTT patients was 80.4%, 75.7%, 64.0%, 64.0%, and 64.0%, respectively, for 1, 3, 5, 7, and 10 years post-transplant, with similar results for non-BTT patients. The freedom from coronary vasculopathy was 90.2%, 90.2%, 72.2%, and 72.2%, respectively, at 1, 3, 5, and 7 years post-transplant. CONCLUSIONS First, to our knowledge, this study is the first to examine the incidence of allosensitization after Novacor implant in detail. In contrast with previous results of work with other VAD systems, as assessed by PRA levels, Novacor patients did not become sensitized. Second, compared with 220 non-BTT patients who received transplants during a similar time frame, Novacor BTT patients had equivalent rejection profiles and survival. Finally, the incidence of transplant-associated coronary artery disease was lower than in previous reports.
Collapse
Affiliation(s)
- David A Baran
- Newark Beth Israel Medical Center, Newark, New Jersey, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Zucker MJ, Baran DA, Arroyo LH, Goldstein DJ, Neacy C, Mele L, Weinberg AD, Prendergast TW, Ribner HS. De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow-Up Analysis. Transplant Proc 2005; 37:2231-9. [PMID: 15964386 DOI: 10.1016/j.transproceed.2005.03.086] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2005] [Indexed: 02/07/2023]
Abstract
BACKGROUND Limited data exist regarding the safety and efficacy of sirolimus in combination with a calcineurin inhibitor in heart transplant recipients. METHODS From January 2001 to June 2002, 31 de novo heart transplant recipients (treatment group) received a combination of sirolimus, tacrolimus, low-dose rabbit antithymocyte globulin, and glucocorticoids. Outcomes, such as actuarial survival, rate of rejection, incidence of infection, probability of developing diabetes mellitus, renal function, platelet and white blood cell counts, and incidence of coronary artery disease at 1 year, were compared with a cohort of 25 patients (control group) who underwent transplantation primarily in 2000 and in early 2002 treated with cyclosporine, mycophenolate mofetil, and glucocorticoids. All patients were followed up for at least 12 months. RESULTS Kaplan-Meier actuarial 1-year survival rates were equivalent between groups (97% for the treatment group and 88% for the control group), as was freedom from allograft rejection (48% and 42% for treatment and control groups, respectively). No cases of transplant arteriopathy were noted within the first posttransplantation year. Renal function was not significantly affected in either group. There was a striking increased incidence of mediastinitis in the treatment group (19%) versus 0% in the control group (P = .02). Tacrolimus-sirolimus therapy was associated with a nearly 11-fold increased incidence of new-onset diabetes mellitus as well (P = .004). CONCLUSION Tacrolimus, sirolimus, and steroids (following low-dose rabbit antithymocyte globulin) were associated with an increased incidence of mediastinitis and posttransplantation diabetes mellitus. No obvious long-term benefit on survival, arteriopathy, or renal function was noted.
Collapse
Affiliation(s)
- M J Zucker
- Cardiothoracic Transplantation Program, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, NJ 07112, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, Fisher PE, Gass A, Greenberg J, Kobashigawa J, Mancini D, Rayburn B, Zucker MJ. Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study). J Heart Lung Transplant 2005; 23:701-8. [PMID: 15366430 DOI: 10.1016/j.healun.2003.07.017] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND We evaluated a new marker of heart transplant rejection, the breath methylated alkane contour (BMAC). Rejection is accompanied by oxidative stress that degrades membrane polyunsaturated fatty acids, evolving alkanes and methylalkanes, which are excreted in the breath as volatile organic compounds (VOCs). METHODS Breath VOC samples (n = 1,061) were collected from 539 heart transplant recipients before scheduled endomyocardial biopsy. Breath VOCs were analyzed by gas chromatography and mass spectroscopy, and BMAC was derived from the abundance of C4-C20 alkanes and monomethylalkanes. The "gold standard" of rejection was the concordant set of International Society for Heart and Lung Transplantation (ISHLT) grades in biopsies read by 2 reviewers. RESULTS Concordant biopsies were: Grade 0, 645 of 1,061 (60.8%); 1A, 197 (18.6%); 1B, 84 (7.9%); 2, 93 (8.8%); and 3A, 42 (4.0%). A combination of 9 VOCs in the BMAC identified Grade 3 rejection (sensitivity 78.6%, specificity 62.4%, cross-validated sensitivity 59.5%, cross-validated specificity 58.8%, positive predictive value 5.6%, negative predictive value 97.2%). Site pathologists identified the same cases with sensitivity of 42.4%, specificity 97.0%, positive predictive value 45.2% and negative predictive value 96.7%. CONCLUSIONS A breath test for markers of oxidative stress was more sensitive and less specific for Grade 3 heart transplant rejection than a biopsy reading by a site pathologist, but the negative predictive values of the 2 tests were similar. A screening breath test could potentially identify transplant recipients at low risk of Grade 3 rejection and reduce the number of endomyocardial biopsies.
Collapse
|
34
|
Phillips M, Boehmer JP, Cataneo RN, Cheema T, Eisen HJ, Fallon JT, Fisher PE, Gass A, Greenberg J, Kobashigawa J, Mancini D, Rayburn B, Zucker MJ. Prediction of heart transplant rejection with a breath test for markers of oxidative stress. Am J Cardiol 2004; 94:1593-4. [PMID: 15589029 DOI: 10.1016/j.amjcard.2004.08.052] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2004] [Revised: 08/06/2004] [Accepted: 08/06/2004] [Indexed: 10/26/2022]
Abstract
The Heart Allograft Rejection: Detection with Breath Alkanes in Low Levels study evaluated a breath test for oxidative stress in heart transplant recipients, and we report here a mathematical model predicting the probability of grade 3 rejection. The breath test divided the heart transplant recipients into 3 groups: positive for grade 3 rejection, negative for grade 3 rejection, and intermediate. The test was 100% sensitive for grade 3 heart transplant rejection when the p value was >/=0.98, and 100% specific when the p value was </=0.058; in the intermediate group, the breath test determined the probability of grade 3 rejection and the predictive value of the result.
Collapse
|
35
|
Abstract
Mycobacterial infections are a well-known, potentially serious, albeit infrequent complication of solid-organ transplantation. Nontuberculous mycobacteria generally account for less than 50% of all such isolates in this patient population. Mycobacterium xenopi, an environmentally ubiquitous organism and common contaminant of hospital hot water systems, is a particularly uncommon isolate after transplantation and has never been reported in heart allograft recipients. We report the occurrence of cavitary M. xenopi infection in an immunocompromised heart transplant recipient in which all the diagnostic criteria of the American Thoracic Society were met. To our knowledge, this is the first such case in a heart transplant recipient described in the literature. Despite therapy, to which the isolates were sensitive in vitro, the patient developed extensive lung cavitation and nodules and succumbed 5 months later to allograft rejection, chronic allograft vasculopathy, and pneumonia.
Collapse
Affiliation(s)
- E Bishburg
- Department of Medicine, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
| | | | | | | |
Collapse
|
36
|
Baran DA, Galin ID, Zucker MJ, Alvi S, Arroyo LH, Lubitz S, Kaplan S, Correa R, Courtney MC, Chan M, Spielvogel D, Lansman SL, Gass AL. Can initial tacrolimus trough levels be predicted from clinical variables? Transplant Proc 2004; 36:2816-8. [PMID: 15621157 DOI: 10.1016/j.transproceed.2004.09.037] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In eligible patients, cardiac transplantation has become the definitive treatment for end-stage heart failure. The initial posttransplantation course is marked by many potential difficulties, including renal insufficiency, hemodynamic instability, and perioperative bleeding. It is important to prevent early rejection; calcineurin inhibitors, such as tacrolimus or cyclosporine, are integral parts of such management. However, these drugs are associated with renal toxicity in some patients. Previous work suggests that limiting the increase in tacrolimus levels is associated with less renal insufficiency. The hypothesis of the current study was that a combination of clinical or laboratory variables could identify patients at risk for rapid changes in tacrolimus target levels. No single variable was strongly associated with high resultant trough levels following a standard 1-mg oral "test dose" of tacrolimus. However, the combination of 2 indices of liver metabolism (alanine aminotransferase and total bilirubin) along with serum creatinine did identify patients who tended toward elevated levels of tacrolimus (> or =4.5 ng/dL). Other variables, such as demographics, and even functional variables, such as right ventricular function by echocardiography, did not enhance the predictive value of this simple scoring system.
Collapse
Affiliation(s)
- D A Baran
- Cardiothoracic Transplantation Program, Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Abstract
OBJECTIVE To increase awareness of giant cell myocarditis (GCM), its pathogenesis, and treatment. METHODS Review of relevant publications from the English-language literature. RESULTS GCM is a rare, frequently fatal inflammatory disorder of cardiac muscle of unknown origin, characterized by widespread degeneration and necrosis of myocardial fibers.Congestive heart failure and ventricular tachycardia are common clinical manifestations. GCM occurs primarily in previously healthy adults, although it is frequently associated with various systemic diseases, primarily of autoimmune causes. The inflammatory infiltrate is characterized by the presence of multinucleated giant cells and is distinct from cardiac sarcoidosis. Animal models of GCM are similar to models of other autoimmune disorders such as rheumatoid arthritis. The prognosis, which is poor despite partial responsiveness to immunosuppressive medications, is improved with cardiac transplantation. CONCLUSIONS The clinical and immunopathogenetic similarities with classical rheumatologic diseases, the differential diagnosis with sarcoidosis and other inflammatory conditions, and the use of standard immunosuppressive medications make GCM a disease process that should be added to the rheumatologist's expertise.
Collapse
Affiliation(s)
- E D Rosenstein
- Division of Rheumatology and Arthritis and Rheumatic Disease Center, St. Barnabas Medical Center, Livingston, NJ 07039, USA.
| | | | | |
Collapse
|
38
|
Zucker MJ, Fuzesi L, Bausback-Aballo S, Shah S, Parsonnet V, Ribner HS. Cardiac transplantation in New Jersey. N J Med 1993; 90:292-4. [PMID: 8506089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Heart transplantation is an effective treatment for end-stage congestive heart failure resulting in a one-year survival of 80 percent and a return to normal function in 90 percent of survivors. Refinements in the pre- and postoperative medical management of transplant recipients portend further benefits.
Collapse
|
39
|
Chadha I, Zucker MJ, Mahmood S, Fuzesi L. Immunosuppression: tomorrow and beyond. N J Med 1993; 90:330-1. [PMID: 8506100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Balancing the benefits and side effects of immunosuppressive therapy is important in transplant patients. Several new agents appear to be safer, more effective, and more specific than the available standard immunosuppressive drugs. Many of the agents are likely to be used with present drugs.
Collapse
Affiliation(s)
- I Chadha
- Newark Beth Israel Medical Center, NJ 07112
| | | | | | | |
Collapse
|
40
|
Fuzesi L, Kirby T, Zucker MJ, McDonough M, Gielchinsky I. Lung transplantation in New Jersey. N J Med 1993; 90:314-6. [PMID: 8506095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Single- or bilateral-lung transplantation is an effective treatment for end-stage pulmonary diseases. Refinements in the surgical technique and postoperative management of recipients have resulted in a return to normal function in most cases and a one-year survival in 70 percent of patients.
Collapse
Affiliation(s)
- L Fuzesi
- Cardiopulmonary Transplantation Program, Newark Beth Israel Medical Center, NJ 07112
| | | | | | | | | |
Collapse
|
41
|
Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Zucker MJ, Pifarré R, Lawless CE, Robinson JA, Scanlon PJ. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 1990; 9:526-37. [PMID: 2231091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We reviewed the transpulmonary gradient, pulmonary arterial systolic pressure, pulmonary vascular resistance (Wood units), and pulmonary vascular resistance index (Wood units X Body surface area), recorded preoperatively in 109 recipients aged 44.6 +/- 13.5 (mean +/- SD) years who underwent orthotopic heart transplantation between March 1984 and March 1988, to identify which measure of pulmonary hypertension most accurately predicts poor outcome after orthotopic heart transplantation. These recipients were followed up as many as 57 (24.7 +/- 14.5) months after their transplant procedure. Preoperative hemodynamic values were as follows: transpulmonary gradient, 10.4 +/- 4.7 mm Hg; pulmonary artery systolic pressure, 53.6 +/- 14.8 mm Hg; pulmonary vascular resistance, 2.7 +/- 1.8 Wood units; pulmonary vascular resistance index, 4.9 +/- 2.7. Nineteen recipients died within 1 year after orthotopic heart transplantation. Causes of death were acute rejection (8), chronic rejection (1), infection (2), nonspecific orthotopic heart transplant failure (4), bowel ischemia (1), pancreatitis (1), lymphoma (1), and liver failure (1). Preoperative pulmonary arterial systolic pressure, pulmonary vascular resistance, and pulmonary vascular resistance index were not predictive of 1-month, 6-month, or 1-year mortality. One-month mortality rates of orthotopic heart transplant recipients with transpulmonary gradient greater than or equal to 12 mm Hg and of those with transpulmonary gradient less than 12 mm Hg were not significantly different (11% vs 3%; p = 0.12). The 6-month mortality rate of orthotopic heart transplant recipients with transpulmonary gradient greater than or equal to 12 mm Hg, however, was five times greater than that of orthotopic heart transplant recipients with transpulmonary gradient less than 12 mm Hg (24% vs 5%; p = 0.003), and 12-month mortality of orthotopic heart transplant recipients with transpulmonary gradient greater than or equal to 12 mm Hg was increased sevenfold when compared with that of orthotopic heart transplant recipients with transpulmonary gradient less than 12 mm Hg (36% vs 5%; p = 0.0005). These results suggest that presently used measures of pulmonary hypertension do not predict mortality in the first month after orthotopic heart transplantation, but that elevated preoperative transpulmonary gradient is associated with a significant increase in mortality at 6 and 12 months after orthotopic heart transplantation. Prospective randomized trials are needed to determined whether extended preload and afterload reduction before and/or after transplant will favorably influence long-term prognosis of orthotopic heart transplant recipients with elevated preoperative transpulmonary gradient.
Collapse
Affiliation(s)
- K W Erickson
- Section of Cardiology, Hines Veterans Administration Medical Center, Ill
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Blakeman BM, Pifarré R, Sullivan H, Costanzo-Nordin MR, Zucker MJ. High-risk heart surgery in the heart transplant candidate. J Heart Transplant 1990; 9:468-72. [PMID: 2231085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Because of the limited supply of donor hearts, transplant physicians are searching for alternative treatments for patients referred for orthotopic heart transplantation. A group of 20 patients (7% of patients accepted for heart transplantation at Loyola University Medical Center) were nonrandomly sent for conventional heart surgery. Of 20 patients, 17 survived their hospitalization, and 11 of the original 20 have avoided heart transplantation or having their names added to the transplant list. This group represents a high-risk subset of patients. Patients with poor ventricular function and ventricular arrhythmias or with poor ventricular function who underwent first-time revascularization were well served by more conventional heart surgery (all 10 patients survived surgery). Patients with poor ventricular function who required redo bypass operation had a poor result (three of six died), and such patients should be considered carefully for initial heart transplantation.
Collapse
Affiliation(s)
- B M Blakeman
- Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, Ill
| | | | | | | | | |
Collapse
|
43
|
Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Winters GL, Pifarre R, Radvany R, Zucker MJ, Scanlon PJ, Robinson JA. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 1990; 9:306-15. [PMID: 2113094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
To compare monoclonal anti-T3-receptor antibody (OKT3) and horse antithymocyte globulin (HATG) immunoprophylaxis, 23 heart transplant recipients were randomized to OKT3 (N = 12) 5 mg IV x 14 days of HATG (N = 11) 5 mg/kg IV x 10 days and followed up for 216 +/- 137 days receiving triple immunosuppression. Recipient groups were demographically and clinically similar. First rejection occurred later in OKT3 recipients vs HATG recipients (31.7 +/- 18.3 vs 15.1 +/- 2.3 days; p less than 0.01), but the first rejection necessitating intensified immunosuppression occurred at similar times (30.9 +/- 14.6 vs 21.9 +/- 10.2 days; NS). Phenotypic characterization of peripheral blood lymphocytes by flow cytometry revealed that OKT3 and HATG recipients had similar decreases in total T lymphocytes and lymphocyte subpopulations. During the follow-up period rejection rates in the OKT3- and in the HATG-treated patients were 3.4 +/- 2.7 and 5.9 +/- 4.7, respectively (NS). The number of rejection episodes per recipient treated with intensified immunosuppression was 1.4 +/- 1.2 in the OKT3- and 2.0 +/- 3.1 in the HATG-treated patients (NS). Infection rates were 4.9 +/- 5.2 in the OKT3- and 2.7 +/- 1.7 in the HATG-treated patients (NS). The number of infection episodes that necessitated intravenous antimicrobial therapy was 2.7 +/- 2.3 in the OKT3- and 1.6 +/- 1.3 in the HATG-treated recipients (NS). The number and length of hospitalizations were similar in patients given OKT3-based or HATG-based immunoprophylaxis. We conclude that immunosuppressive prophylaxis with OKT3 vs HATG in heart transplant recipients is associated with a slightly lower incidence and severity of rejection and slightly higher infection rates.
Collapse
|
44
|
Winters GL, Costanzo-Nordin MR, O'Sullivan EJ, Pifarré R, Silver MA, Zucker MJ, Robinson JA, Scanlon PJ. Predictors of late acute orthotopic heart transplant rejection. Circulation 1989; 80:III106-10. [PMID: 2805288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
To identify predictors of late acute rejection after orthotopic heart transplantation (OHT), 53 patients who received transplants between March 1984 and March 1987 and who survived at least 1 year postoperatively were followed up for 402-1,151 days (mean, 841 days). Fourteen patients experienced 22 moderate or severe rejection episodes more than 1 year after OHT (LR); 39 were nonrejectors (NR). Twelve of 14 (86%) LR and only 14 of 39 (36%) NR had two or more moderate or severe rejection episodes within the first year after OHT (p less than 0.001). The LR had significantly higher numbers of infections more than 1 year after OHT (2.0 vs. 0.9; p less than 0.05). Nine of 22 (40%) late acute rejection episodes followed within 1 month of infection. Human leukocyte antigen reactivity before OHT, follow-up hemodynamics, length of survival, incidence of diabetes mellitus, coronary artery disease 1 year after OHT, mean cyclosporine levels, and mean daily prednisone doses were similar in LR and NR patients. We conclude that 1) OHT recipients with two or more moderate or severe rejection episodes in the first year after OHT are at higher risk of developing late acute rejection and may require closer long-term rejection surveillance and more aggressive maintenance immunosuppression and 2) the possible relation between infection and subsequent acute rejection episodes in OHT recipients requires further investigation.
Collapse
Affiliation(s)
- G L Winters
- Department of Pathology, Loyola University Medical Center, Maywood, IL 60153
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Costanzo-Nordin MR, O'Sullivan EJ, Hubbell EA, Zucker MJ, Pifarre R, McManus BM, Winters GL, Scanlon PJ, Robinson JA. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience. J Heart Transplant 1989; 8:288-95. [PMID: 2504895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
We describe the long-term follow-up of 25 patients treated with murine antihuman mature T cell (OKT3) monoclonal antibody at Loyola University Medical Center. After OKT3 rescue therapy, 12 patients were monitored for 16.5 +/- 6.5 months. Twenty-two moderate and three severe rejection episodes occurred 11 to 469 days (166.8 +/- 126.0) after OKT3 therapy in nine of 12 patients. During the follow-up period three patients died, and one required retransplantation because of recurrent rejection. The coronary arteries of three failed allografts had severe intimal thickening and infiltration with lymphocytes. Thirteen patients received OKT3 for prophylactic immunosuppression, and their course was compared to that of 13 patients who underwent transplantation during the same period but were given prophylactic horse antihuman thymocyte globulins (HATG). There were no differences between the two drugs with respect to long-term incidence and severity of rejection and infection, cardiac allograft function, and survival. Our results indicate that, despite successful reversal with OKT3, heart transplant recipients with refractory rejection remain plagued by recurrent rejection. Cardiac allografts in recipients who die as a result of recurrent rejection show evidence of immune-mediated vasculitis, which results in severe and diffuse coronary luminal narrowing. OKT3 and HATG appear to be equally effective for rejection prophylaxis.
Collapse
|
46
|
Ribner HS, Zucker MJ, Stasior C, Talentowski D, Stadnicki R, Lesch M. Vasodilators as first-line therapy for congestive heart failure: a comparative hemodynamic study of hydralazine, digoxin, and their combination. Am Heart J 1987; 114:91-6. [PMID: 3604877 DOI: 10.1016/0002-8703(87)90312-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Although digitalis and vasodilators both enhance cardiac performance in patients with congestive heart failure, their relative efficacy is unknown. Accordingly, the acute hemodynamic effects of intravenous hydralazine (0.15 mg/kg), digoxin (1.0 mg), and the hydralazine-digoxin combination were evaluated in 14 normotensive heart failure patients at sitting rest, nine of whom were also studied during submaximal upright bicycle exercise. Hemodynamic responses at rest and exercise were similar. Cardiac output and stroke volume rose with both agents, the increase in cardiac output with hydralazine exceeding that with digoxin at rest. Left and right ventricular filling pressures declined equally. Systemic arterial mean pressure and total systemic vascular resistance fell with hydralazine, while, with digoxin, systemic arterial mean pressure increased and total systemic vascular resistance was unchanged. The hydralazine-digoxin combination produced increases in cardiac output and stroke volume that were greater than with either drug alone, and that equalled the sum of the drugs' individual effects; reductions in ventricular filling pressures were similar to the single-drug interventions. Thus, hydralazine is at least as effective as digoxin in improving cardiac function over the short term. Vasodilators may constitute an acceptable alternative to digitalis as initial therapy for congestive heart failure, except where a reduction in systemic arterial pressure is potentially deleterious. Use of combined treatment produces greater increases in cardiac output than with either drug alone, but requires risking the toxicities of two agents.
Collapse
|